Pretax income is the income that a company earns before paying income taxes. Xvivo Perfusion AB's pretax income for the
three
months ended in Mar. 2026 was $4.60 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2026 was $10.25 Mil.
Xvivo Perfusion AB's pretax margin was 17.78%.
During the past 13 years, Xvivo Perfusion AB's highest Pretax Margin was 24.31%. The lowest was -31.84%. And the median was 4.89%.
Xvivo Perfusion AB (OTCPK:XVIPF) Pre-Tax Income Explanation
Xvivo Perfusion AB's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as
During the past 13 years, Xvivo Perfusion AB's highest Pretax Margin was 24.31%. The lowest was -31.84%. And the median was 4.89%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB Pre-Tax Income Related Terms
Xvivo Perfusion AB Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Xvivo Perfusion AB's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Pre-Tax Income vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (XVIPF) has a Pre-Tax Income of $10.25 Mil as of Mar. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Xvivo Perfusion AB and its competitors.
Is Xvivo Perfusion AB's Pre-Tax Income too high?
Xvivo Perfusion AB's current Pre-Tax Income is $10.25 Mil. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Pre-Tax Income compare to ABT and SYK?
Xvivo Perfusion AB's Pre-Tax Income of $10.25 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Medical Devices & Instruments company?
A good Pre-Tax Income depends on the Medical Devices & Instruments industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current Pre-Tax Income is $10.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $41.74, compared to a current price of $29.00 — trading 30.5% below its estimated fair value. The current Pre-Tax Income is $10.25 Mil. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Pre-Tax Income is $10.25 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 30.5% below its estimated GF Value™ of $41.74.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Pre-Tax Income: $10.25 Mil
GF Value™: $41.74 vs. price of $29.00 (30.5% below fair value)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
